Abstract
Interferon-alpha (IFN-α) has been applied for treatment of several ma-lignancies e.g. hairy cell leukemia (HCL) (7,16,19,28), chronic myelogenous leukemia (CML) (24,25), non-Hodgkin lymphomas (NHL) (2,3), renal cell cancer (RCC) (4,20,27), malignant melanoma (8), and Kaposi’s Sarcoma (26). So far, the therapeutic efficacy seems to be more evident in hematologic malignancies than in solid tumors. For example, high response rates (80%) have been shown in HCL and in CML (16,24,25) and lower but relevant response rates (30% or less) have been reported in studies on RCC and melanoma (4,8,20). These results are sufficient to select patients who will benefit very likely from IFN-α therapy. However, one should not draw premature negative conclusions about the lack of efficacy of IFN- if a particular design of a study gives negative results. HCL and RCC are used as examples in this report to provide some evidence that not only IFN doses and treatment regimens but also the source of IFNs may be variables which can considerably influence the results of clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
